Literature DB >> 9818037

Prolactinomas in male and female patients: a comparative clinicopathologic study.

R D Calle-Rodrigue1, C Giannini, B W Scheithauer, R V Lloyd, P C Wollan, K T Kovacs, L Stefaneanu, A B Ebright, C F Abboud, D H Davis.   

Abstract

OBJECTIVE: To explore the basis of the gender-based differences in endocrine and surgical findings in patients with prolactinoma (prolactin cell adenoma) as well as in their clinical outcome.
MATERIAL AND METHODS: In young or reproductive-age female patients, older women (beyond 40 years of age), and male patients, we systematically studied the following factors: operative and endocrine features (tumor size, invasiveness, preoperative serum prolactin level, and biochemical outcome), specific biologic variables (mitotic index, MIB-1 labeling index, and p27 immunoreactivity), and hormone receptor status (estrogen and progesterone receptor proteins as well as dopamine D2 receptor messenger RNA).
RESULTS: Of the various factors assessed, the preoperative prolactin level and MIB-1 labeling index were lower in young female patients in comparison with older female and particularly male patients. Hormone levels were also positively associated with mitotic activity as well as the MIB-1 labeling index. Although invasion was infrequent in microadenomas of young female patients, no statistically significant differences in tumor size or invasiveness were noted among the three patient groups. Absence of differences in invasiveness may, in part, be explained by artifacts of case selection.
CONCLUSION: The basis for the observed differences in proliferative activities in tumors of the three study groups is not readily apparent but may reflect differences in the endocrine milieu or the effect of sex steroid hormone receptors, tumoral vascularity, or specific growth factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818037     DOI: 10.4065/73.11.1046

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  16 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  The epidemiology of prolactinomas.

Authors:  Antonio Ciccarelli; Adrian F Daly; Albert Beckers
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.

Authors:  D Kojo Hamilton; Mary Lee Vance; Paul T Boulos; Edward R Laws
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 5.  PRL secreting adenomas in male patients.

Authors:  Antonio Ciccarelli; Ermelinda Guerra; Michele De Rosa; Francesco Milone; Stefano Zarrilli; Gaetano Lombardi; Annamaria Colao
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 6.  Cancer in Transgender People: Evidence and Methodological Considerations.

Authors:  Hayley Braun; Rebecca Nash; Vin Tangpricha; Janice Brockman; Kevin Ward; Michael Goodman
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

7.  Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.

Authors:  Mirta Knoepfelmacher; Miriam C Gomes; Maria E Melo; Berenice B Mendonca
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

8.  Women with prolactinomas presented at the postmenopausal period.

Authors:  Ilan Shimon; Marcello D Bronstein; Jonathan Shapiro; Gloria Tsvetov; Carlos Benbassat; Ariel Barkan
Journal:  Endocrine       Date:  2014-04-08       Impact factor: 3.633

Review 9.  Hyperprolactinemia in men: clinical and biochemical features and response to treatment.

Authors:  Michele De Rosa; Stefano Zarrilli; Antonella Di Sarno; Nicola Milano; Maria Gaccione; Bartolomeo Boggia; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

Review 10.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.